My group uses genome-wide functional genetic approaches to identify powerful drug combinations, new drug targets and mechanisms of resistance to cancer drugs. We focus on induction of senescence as a new therapeutic modality for cancer therapy.
In addition, we study how combinations of drugs that act in the MAP kinase pathway can help improve responses in patients with perturbations of this pathway. We aim to bring our discoveries to the clinic in close collaboration with the clinicians of our affiliated hospital.
